LDFR
SRNE

Lehman & Derafelo Financial Resources’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Lehman & Derafelo Financial Resources’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$63K – 301
2020
Q2 		$63K Buy
+10,000
New +$38.3K 0.02% 153

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lehman & Derafelo Financial Resources's SRNE Position: Q4 2020 in Review

Lehman & Derafelo Financial Resources sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 3,100 shares — an estimated $35K sold.

Lehman & Derafelo Financial Resources first reported a position in SRNE in Q2 2020 and held it in 2 quarters. The position peaked at $35K in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Lehman & Derafelo Financial Resources reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Lehman & Derafelo Financial Resources sold 3,100 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $35K.
  • Lehman & Derafelo Financial Resources first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
  • Lehman & Derafelo Financial Resources's Sorrento Therapeutics, Inc. position peaked at $35K in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Lehman & Derafelo Financial Resources's 13F filing for Q4 2020, filed 20 Jan 2021.